Since GLP-1 drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide took the world by storm for their potent treatment of diabetes and obesity, they have also been plagued by a clinical conundrum. In some studies, the peptides seem to possess antidepressant effects, while in others they’ve been linked to worse mental health and even increased suicidality.